Determination of Serum D-Dimer Levels in Breast Cancer Patients Referred to Imam Sajjad Hospital in Ramsarin 2016

Authors
Faegheh Sadat Mousavi Khorshidi
Shahrbanoo Keihanian
Maryam Zakerihamidi
Abstract
Introduction

Breast cancer is one of the most common cancers among women and is spreading with the highest rate in developing countries. The aim of this study was to evaluate serum levels of D-dimer in patients with breast cancer.

Materials and Methods

: In this cross-sectional study, 100 the patients with the diagnosis of breast cancer who have been admitted at Imam Sajjad Hospital for further treatment were enrolled.

Results

The average serum D-dimer in stage IV was 628±304, in stage III was 229±101 and in stage II was 180±29. In addition, the frequency of abnormal D-dimer was higher in patients at stage IV. The D-dimer level and the frequency of abnormal D-dimer level were higher in patients with lymph node involvement. Moreover, patients who had abnormal CEA and CA15-3 tumor markers had higher D-dimer level. We have also found serum D-dimer levels in patients 41-50 years old group was higher than other groups.

Conclusion

In general, increase in serum D-dimer levels are associated with advanced disease stage, lymph node involvement, and worse prognosis and since the D-dimer is a safe, inexpensive, and available marker can be used to assess prognosis of disease and survival of the patients
Keywords
Breast Cancer
D-dimer
prognosis of disease
Ramsar
Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2(3):133-40.
Kumar V, Abbas A, Aster J. Robbins basic pathology: Elsevier Health Sciences; 2012. Available from: URL: https://www.elsevier.com/books/robbins-basic-pathology/kumar/978-1-4377-1781-5.
Lauw MN, van Doormaal FF, Middeldorp S, Buller HR. Cancer and venous thrombosis: current comprehensions and future perspectives. Semin Thromb Hemost 2013; 39(5):507-14.
Bhavesh D, Kapil Dev N, Sudershan S, Jaswal S. Evaluation of Plasma D-Dimer Level as a Predictve Marker of Advanced Carcinoma Breast. J Clin Case Rep 2015; 5(6).
Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62(2):126-36.
Khan MZ, Khan MS, Raziq F, Khattak AM. Fibrinogen degradation products and D-dimers in patients with breast carcinoma. Gomal Journal of Medical Sciences. 2007; 5(1):9-12.
Batschauer AP, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LM, Fernandes AP, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol 2010; 21(6):1267-72.
Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86(3):389-95.
Dastjerdi MV, Ahmari S, Alipour S, Tehranian A. The comparison of plasma D-dimer levels in benign and malignant tumors of cervix, ovary and uterus. Int J Hematol Oncol Stem Cell Res 2015; 9(3):107-11.
Chaari M, Ayadi I, Rousseau A, Lefkou E, Van Dreden P, Sidibe F, et al. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability. BMC cancer 2014; 14(1):991.
Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica 2012; 97(8):1158-64.
Aliustaoglu M, Yumuk PF, Gumus M, Ekenel M, Bolukbas F, Bolukbas C, et al. D-dimer-can it be a marker for malignant gastric lesions?. Acta Oncol 2004; 43(8):770-1.
Tas F, Ciftci R, Kilic L, Bilgin E, Keskin S, Sen F, et al. Clinical and prognostic significance of coagulation assays in melanoma. Melanoma Res 2012; 22(5):368-75.
Kwon H-C, Oh SY, Lee S, Kim S-H, Han JY, Koh RY, et al. Plasma levels of prothrombin fragment F1+ 2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol 2008; 38(1):2-7.